Press Releases

Lineage Cell Therapeutics to Ring Opening Bell at the New York Stock Exchange on August 21, 2019

August 20, 2019 at 8:00 AM EDT

CARLSBAD, Calif.--(BUSINESS WIRE)--Aug. 20, 2019-- Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs, today announced that members of Lineage's executive leadership team and Board of Directors will ring The Opening Bell® at the New York Stock Exchange (NYSE) on Wednesday, August 21, 2019. The Company is ringing The Opening Bell at the NYSE to highlight the formal launch of its new corporate brand, which reflects its commitment to establish itself as a leading cell therapy company.

"We are honored to have been invited by the New York Stock Exchange to participate in The Opening Bell ceremony and highlight our new corporate brand and identity,” stated Brian M. Culley, the Company’s Chief Executive Officer. “Our plan for the remainder of 2019 includes continuous and productive engagement with the investment and medical communities, such as presenting at important healthcare industry and medical conferences. We expect that these steps will provide broader exposure as data from our innovative product candidates becomes available. We believe this is an exciting time in our development thanks to strategic actions we have taken to invest more fully in our core competencies, and we intend to broadly communicate our clinical progress, manufacturing expertise, and intellectual property position.”

Industry and medical conference presentations confirmed to date include:

In addition to live television coverage of the ceremony, the NYSE will stream The Opening Bell® ringing on its website: https://www.nyse.com/bell. The bell ringing is scheduled for 9:26 - 9:30 a.m. ET. A video of the bell-ringing will also be archived on that same page after the livestream.

About Lineage Cell Therapeutics, Inc.

Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs. Lineage’s programs are based on its proprietary cell-based therapy platform and associated development and manufacturing capabilities. With this platform Lineage develops and manufactures specialized, terminally-differentiated human cells from its pluripotent and progenitor cell starting materials. These differentiated cells are developed either to replace or support cells that are dysfunctional or absent due to degenerative disease or traumatic injury or administered as a means of helping the body mount an effective immune response to cancer. Lineage’s clinical assets include (i) OpRegen®, a retinal pigment epithelium transplant therapy in Phase I/IIa development for the treatment of dry age-related macular degeneration, a leading cause of blindness in the developed world; (ii) OPC1, an oligodendrocyte progenitor cell therapy in Phase I/IIa development for the treatment of acute spinal cord injuries; and (iii) VAC2, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells currently in Phase I development for the treatment of non-small cell lung cancer. For more information, please visit www.lineagecell.com or follow the Company on Twitter @LineageCell.

Forward-Looking Statements

Lineage cautions you that all statements, other than statements of historical facts, contained in this press release, are forward-looking statements. Forward-looking statements, in some cases, can be identified by terms such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “design,” “intend,” “expect,” “could,” “plan,” “potential,” “predict,” “seek,” “should,” “would,” “contemplate,” “project,” “target,” “tend to,” or the negative version of these words and similar expressions. Such statements include, but are not limited to, statements relating to Lineage’s planned investor relations campaign. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Lineage’s actual results, performance or achievements to be materially different from future results, performance or achievements expressed or implied by the forward-looking statements in this press release, including risks and uncertainties inherent in Lineage’s business and other risks described in Lineage’s filings with the Securities and Exchange Commission (SEC). Lineage’s forward-looking statements are based upon its current expectations and involve assumptions that may never materialize or may prove to be incorrect. All forward-looking statements are expressly qualified in their entirety by these cautionary statements. Further information regarding these and other risks is included under the heading “Risk Factors” in Lineage’s periodic reports filed with the SEC, including Lineage’s Annual Report on Form 10-K filed with the SEC on March 14, 2019 and its other reports, which are available from the SEC’s website. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date on which they were made. Lineage undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.

Source: Lineage Cell Therapeutics, Inc.

Lineage Cell Therapeutics, Inc. IR
Ioana C. Hone
(ir@lineagecell.com)
(510) 871-4188

Solebury Trout IR
Gitanjali Jain Ogawa
(Gogawa@troutgroup.com)
(646) 378-2949